Metabolic activity and cell viability assays demonstrated that ELR nanoparticles carrying the Akt inhibitor significantly reduced the metabolic activity and viability of pancreatic cancer cells in a dose- and time-dependent manner. The gene discussed is AKT1; the disease is pancreatic neoplasm.